We highlight the most frequently mutated genes (TP53, EGFR, KRAS, CDKN2A, and STK11) and most frequently reported missense mutations (L858R in EGFR and G12C in KRAS) in BM derived from NSCLC, and assessed their potential clinical actionability. This evidence concerns the gene STK11 and non-small cell lung carcinoma.